Focused On-demand Library for Selenocysteine insertion sequence-binding protein 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q96T21

UPID:

SEBP2_HUMAN

Alternative names:

Alternative UPACC:

Q96T21; F8W892; Q5HYY1; Q7L1Z0; Q8IYC0; Q9H0A1

Background:

Selenocysteine insertion sequence-binding protein 2, encoded by the gene with accession number Q96T21, plays a pivotal role in the synthesis of selenoproteins. It specifically binds to the SECIS element in the 3'-UTR of mRNAs encoding selenoproteins, a process that is enhanced by SELB. This binding is crucial for the incorporation of selenocysteine into proteins, an essential step in selenoprotein synthesis.

Therapeutic significance:

The protein is linked to 'Thyroid hormone metabolism, abnormal, 1', a disorder stemming from reduced activity of type II iodothyronine deiodinase. Understanding the role of Selenocysteine insertion sequence-binding protein 2 could open doors to potential therapeutic strategies for managing thyroid hormone-related disorders.